Drug-Drug Interactions Potential of Direct Acting Antivirals for the treatment of Chronic Hepatitis C infection

Hepatitis C virus (HCV) infection is still a major global problem. Approximately, 71 million people were living with HCV worldwide in 2017 [1]. The primary objective of HCV treatment is to obtain a complete eradication of the virus, which is characterized as a sustained virological response (SVR). SVR is defined by an undetectable HCV RNA at 12 weeks after the end of treatment [2,3]. The management of HCV-infected patients has rapidly changed in the recent years. After the breakthrough of first-generation direct acting antiviral agents (DAAs), boceprevir and telaprevir, many DAAs targeting specific proteins of the HCV life cycle have been developed: the NS3/4A protease, the NS5A protein, and the NS5B protein [4].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Tags: Themed Issue: Therapeutics of hepatitis viruses Source Type: research